Milestones to optimize of transjugular intrahepatic portosystemic shunt technique as a method for the treatment of portal hypertension complications.
| Autor: | Garbuzenko DV; Department of Faculty Surgery, South Ural State Medical University, Chelyabinsk 454092, Russia. garb@inbox.ru. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | World journal of hepatology [World J Hepatol] 2024 Jun 27; Vol. 16 (6), pp. 891-899. |
| DOI: | 10.4254/wjh.v16.i6.891 |
| Abstrakt: | This editorial describes the milestones to optimize of transjugular intrahepatic portosystemic shunt (TIPS) technique, which have made it one of the main methods for the treatment of portal hypertension complications worldwide. Innovative ideas, subsequent experimental studies and preliminary experience of use in cirrhotic patients contributed to the introduction of TIPS into clinical practice. At the moment, the main achievement in optimize of TIPS technique is progress in the qualitative characteristics of stents. The transition from bare metal stents to extended polytetrafluoroethylene-covered stent grafts made it possible to significantly prevent shunt dysfunction. However, the question of its preferred diameter, which contributes to an optimal reduction of portal pressure without the risk of developing post-TIPS hepatic encephalopathy, remains relevant. Currently, hepatic encephalopathy is one of the most common complications of TIPS, significantly affecting its effectiveness and prognosis. Careful selection of patients based on cognitive indicators, nutritional status, assessment of liver function, etc. , will reduce the incidence of post-TIPS hepatic encephalopathy and improve treatment results. Optimize of TIPS technique has significantly expanded the indications for its use and made it one of the main methods for the treatment of portal hypertension complications. At the same time, there are a number of limitations and unresolved issues that require further randomized controlled trials involving a large cohort of patients. Competing Interests: Conflict-of-interest statement: Author has no conflict of interest to declare. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|